Emerging Role of Eosinophils in Resolution of Arthritis

Yi Qin†, Hui-Zhi Jin†, Yu-Jing Li2 and Zhu Chen‡*

1 Department of Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, División de Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, 2 Second Clinical Medical School, Second Affiliated Hospital of Fujian Medical University, Fujian Medical University, Quanzhou, China

Eosinophils are a minor component of circulating granulocytes, which are classically viewed as end-stage effector cells in host defense against helminth infection and promoting allergic responses. However, a growing body of evidence has emerged showing that eosinophils are versatile leukocytes acting as an orchestrator in the resolution of inflammation. Rheumatoid arthritis (RA) is the most common chronic inflammatory disease characterized by persistent synovitis that hardly resolves spontaneously. Noteworthy, a specific population of eosinophils, that is, regulatory eosinophils (rEos), was identified in the synovium of RA patients, especially in disease remission. Mechanistically, the rEos in the synovium display a unique pro-resolving signature that is distinct from their counterpart in the lung. Herein, we summarize the latest understanding of eosinophils and their emerging role in promoting the resolution of arthritis. This knowledge is crucial to the design of new approaches to rebalancing immune homeostasis in RA, considering that current therapies are centered on inhibiting pro-inflammatory cytokines and mediators rather than fostering the resolution of inflammation.

Keywords: eosinophil, rheumatoid arthritis, resolution, innate lymphoid cells, alternatively activated macrophages

INTRODUCTION

Eosinophils are leukocytes that normally amount to less than 5% of white blood cells in the peripheral blood. In certain pathological settings, eosinophils significantly expand and count over 1,500 cells/μl blood, which is defined as hypereosinophilia (1). Although previously considered as the end-stage effector cells involved in helminth infection and allergic diseases like asthma, increasing evidence shows that eosinophils are multifunctional granulocytes involved in regulating adaptive immune responses, especially in inflammatory and autoimmune disorders (2).

Rheumatoid arthritis (RA) is the most common chronic immune-mediated inflammatory disease characterized by persistent synovitis that lacks self-remission (3). Although the pathogenesis of RA remains incompletely understood, the general consensus is that self-tolerance breakdown triggers autoantibody production in genetically predisposed individuals before progressing into clinically apparent RA (3). During the transition from asymptomatic autoimmunity to synovial inflammation, a diverse range of pro-inflammatory cytokines produced by immune cells such as CD4⁺ T cells, macrophages, and fibroblast-like synoviocytes emerge quickly, which eventually contribute to cartilage damage and bone erosion in the joint (4).
Notably, once the joint inflammation is established, it tends to be chronic, as evidenced by the insufficiency of regulatory factors that counteract or rebalance aberrant immune responses (4). Hence, ineffective resolution of RA remains a major clinical challenge, although novel anti-inflammatory biological agents have been increasingly introduced (5, 6).

In contrast with the pro-inflammatory properties of eosinophils in asthma that cause structural remodeling of the airways, recent studies by us and collaborators have suggested that, as a crucial component of Th2 immune responses, eosinophils have previously undifferentiated pro-resolving signature in RA (7–10). In this review, the emerging role of eosinophils in promoting the resolution of arthritis is summarized. The potential underlying mechanisms that allow eosinophils to exert anti-inflammatory properties and therapeutic implications of eosinophils in arthritis are also discussed.

EOSINOPHIL DEVELOPMENT AND BIOLOGY

Eosinophils are generated in the bone marrow from multipotent hematopoietic stem cells, which give rise to eosinophil-committed progenitors (EoPs). These will eventually differentiate into mature eosinophils in response to several cytokines such as IL-5, IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-33 (11–13). Eosinophilopoiesis is governed by at least three transcription factors, including GATA-1 (a zinc family finger member), PU.1 (an ETS family member), and C/EBP members (CCAAT/enhancer-binding protein family) (14, 15). Notably, GATA-1 is essential for eosinophil differentiation, since the deletion of a GATA-binding enhancer site in the GATA-1 gene generated a specific eosinophil-deficient ΔdblGATA mouse with no influence on other cell lineages (16). In addition, some microRNAs and long non-coding RNAs have been reported to be involved in eosinophilopoiesis (17–19).

Once eosinophils mature in the bone marrow, they are released into circulation and migrate into peripheral tissues under stimulation of IL-5 and eotaxin-1 (CCL11) (2). In homeostatic conditions, eosinophils are distributed in the spleen, gastrointestinal tract, thymus, adipose tissue, and uterus, indicating that they are likely to be responsible for maintaining homeostasis in different tissues (20). It is well established that eosinophils synthesize a broad range of mediators stored in granules throughout the cytoplasm, including cytotoxic granule proteins such as major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPX), and eosinophil-derived neurotoxin (EDN) (21). When encountering the stimulus present in the tissue, eosinophils release granule contents rapidly, which is termed degranulation, to exert host immune defense against pathogens (2). Hence, historically it is considered that the primary effector function of eosinophils was in anti-pathogen responses, especially those involving parasites. Nonetheless, eosinophil granules also contain numerous cytokines, particularly type 2 cytokines, as well as growth factors and resolvins, suggesting their ability to be involved in tissue repair and a wide range of immunological disorders such as allergy and asthma (22, 23).

REGULATION OF TH2 RESPONSES BY EOSINOPHILS

Although they represent a minor component of innate immune cells, eosinophils are well known to be an important innate immune regulator in pathogen clearance by releasing cytokines and chemokines or by interacting with other innate immune cells (24–28). Meanwhile, increasing evidence has extended understanding that eosinophils are versatile leukocytes capable of modulating adaptive immune responses as well. For example, murine eosinophils can present antigen via MHC class II and promote IL-4, IL-5, and IL-13 production from antigen-specific CD4+ T cells in the context of helminth infection or asthma (23, 29, 30).

Other than behaving as antigen-presenting cells, eosinophils are thought to regulate Th2 immune responses in multiple ways. A Notch ligand Jagged1, which constitutes an instructive signal for Th2 differentiation, has been found to express on human eosinophils constitutively, indicating the capability of eosinophils to provide a polarization signal to naïve CD4+ T cells (31, 32). Studies on helminth infection models revealed that eosinophils precede lymphocyte recruitment into inflammatory sites (33, 34). In eosinophil-deficient ΔdblGATA mice infected with Trichinella spiralis, infiltration of Th2 cells into the muscles was highly decreased (35). In another study using IL-5/eotaxin double-knockout mice in which eosinophil counts are severely reduced, significantly decreased IL-13 production by Th2 cells in response to the OVA challenge was observed (36). Notably, this defect can be rescued by the adoptive transfer of eosinophils, suggesting the role of eosinophils in the regulation of Th2 immune responses (36). In addition to the secretion of Th2-related cytokines, eosinophils can also promote Th2 responses through the synthesis of indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes the oxidative catabolism of tryptophan to kynurenines (37).

EOSINOPHILS PROMOTE THE RESOLUTION OF INFLAMMATION

Inflammation is an evolutionary defensive host response to injury, characterized by the recruitment of leukocytes and cytokines from the circulation to the inflamed tissue. Generally, acute inflammation in healthy individuals is self-limited and resolves timely, thus preventing to progress to chronic inflammation (38). During the course of acute inflammation, the migration of polymorphonuclear neutrophils (PMNs) into tissues is the early event, followed by the recruitment of monocytes that will further differentiate into tissue macrophages. It is known that a variety of classic proinflammatory mediators such as prostaglandins (PGs) and leukotrienes (LTs) coordinate these initial events of acute inflammation by regulating vascular permeability and leukocyte infiltration (39). Once the malicious components are removed by
phagocytosis, the inflammatory response must be promptly resolved to prevent excessive tissue damage and return to homeostasis. However, uncontrolled or long-lasting inflammation is believed to exist in the pathogenesis of many human autoimmune and inflammatory diseases including RA (40).

In recent years, a growing body of evidence has emerged that shows that resolution of acute inflammation is not a passive but an active process controlled by endogenous resolving mediators, termed specialized pro-resolving mediators (SPMs) such as protectins, resolvins, and maresins, which belong to families of lipid mediators (41). Blocking lipid mediator biosynthesis by either cyclooxygenase (COX)-2 or lipoxygenase (LOX) inhibitors resulted in resolution defect, which is characterized by sustained leukocyte infiltration in inflamed sites and impaired removal of phagocytes to the draining lymph nodes (42), suggesting the critical role of these lipid mediators in regulating the timely resolution of acute inflammation.

Interestingly, eosinophils are an orchestrator in the resolution of inflammation. In a murine zymosan-induced peritonitis model, eosinophils were recruited to the inflamed site during the resolution phase of acute peritonitis (43). Liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based lipidomics analyses revealed that pro-resolving mediators such as protectin D1 (PD1) were increased during the resolution phase in a 12/15-LOX dependent manner (43). PD1 promotes the resolution process by inhibiting PMN influx and stimulating macrophage ingestion of apoptotic PMNs, as well as increasing phagocyte clearance into draining lymph nodes (42). Importantly, the researchers revealed that eosinophils were the main PD1-producing cells in the resolution phase of zymosan-induced peritonitis (43). Depletion of eosinophils or CXCL13 in vivo caused a resolution defect, characterized by impaired lymphatic drainage of inflammatory phagocytes carrying engulfed zymosan in the draining lymph node, and delayed removal of PMNs in the inflamed tissues (44). Notably, administration of PD1, CXCL13, or adoptive transfer of eosinophils from wild-type but not from 12/15-LOX deficient mice reversed the defective phenotype of the resolution process, suggesting that eosinophils promote the resolution of inflammation through pro-resolving mediators and CXCL13 pathway (43, 44). In another experimental colitis model, more severe colitis was observed in eosinophil-deficient mice compared with wild-type controls, accompanied with decreased level of PD1 in the colon (45). Furthermore, administration of exogenous PD1 alleviated the severity of colitis and reduced neutrophil infiltration. All these findings indicated that eosinophils contribute to the resolution of inflammation by producing pro-resolving lipid mediators such as PD1 via the 12/15-LOX-mediated biosynthetic pathway.

**REGULATORY EOSINOPHILS IN RA**

Although eosinophils act as a counter regulator in several inflammatory disorders, the association between eosinophils and the development of RA was largely undetermined, probably due to the uncommon clinical manifestation of eosinophilia in RA. Indirect evidence from previous studies reported that RA patients, especially those with high activity and short disease duration, have increased serum levels of ECP, supporting the notion that eosinophils were involved in the inflammatory responses of RA (46, 47). In a prospective multi-center cohort study, the prevalence of eosinophilia in patients with new-onset arthritis (disease duration ranges from 6 weeks to 6 months) is only 3.2% (48). Notably, after 3 years, patients with eosinophilia presented with signs of higher disease activity compared with those without eosinophilia at baseline, suggesting that baseline eosinophilia might be a poor prognosis marker in early arthritis patients (48). A more recent prospective observational study investigated clinical characteristics of RA patients with persistent eosinophilia and compared with the patients without eosinophilia (49). After excluding secondary causes of eosinophilia such as concomitant allergic diseases and intestinal helminth infection, the authors did not find differences in clinical features between RA patients with or without eosinophilia (49). The discrepancies among studies might reflect the complex heterogeneity of eosinophil phenotype or function in inflammatory arthritis.

Recently, we have shown that the expression of synovium EPX was elevated in RA patients compared with osteoarthritis (OA) patients (7). Consistently, serum EPX level was higher in RA patients than pre-RA and healthy controls (7). In the K/BxN serum-induced arthritis model, IL-5 transgenic (IL-5tg) mice that have extraordinary hypereosinophilia showed a significant reduction of arthritis score, whereas eosinophil-deficient AdblGATA mice presented with higher disease activity (7). In addition, the adoptive transfer of eosinophils into collagen-induced arthritic mice led to the alleviation of arthritis, accompanied by reduced joint inflammation and bone erosion in histology evaluation (9). Altogether, these data suggested that eosinophils have previous unknown pro-resolving properties in promoting the resolution of inflammatory arthritis.

Considering the dual nature of eosinophils as pro-inflammatory and pro-resolving cells, it is reasonable to speculate that eosinophils have different subsets responsible for different biological functions. Indeed, this is supported by the research that revealed two distinct eosinophil subsets, lung resident eosinophils and recruited inflammatory eosinophils, in asthmatic lungs (50). Remarkably, a very recent study described a specific population of eosinophils, named regulatory eosinophils (rEos), was present in the joints of arthritic mice as well as synovium of RA patients (8). OVA allergen challenge triggered an earlier resolution of K/BxN serum-induced arthritis, accompanied with increased eosinophils in the arthritic joints. Strikingly, this protective manifestation was only observed in wild-type but not eosinophil-deficient AdblGATA mice, indicating the essential role of eosinophils in the asthma-induced resolution of joint inflammation (8). In further analyses, both single-cell RNA sequencing and proteome profile analyses confirmed that the rEos in the joint display a unique pro-resolving characteristic, which is distinct from their counterpart in the lung. For example, joint rEos have strongly upregulated expression of 5-LOX and 12/15-LOX (8), which could explain the anti-inflammatory and pro-resolving effector function of rEos, since the deletion of 12/15-LOX was linked to
uncontrolled inflammation and tissue damage in chronic arthritis (51). Moreover, rEos has a specific secretion pattern compared with its inflammatory counterpart in the lung, characterized by the production of MMP-3, osteopontin, and serpin E1, suggesting that rEos might also foster synovial tissue recovery besides ceasing inflammation (8). Interestingly, rEos was infiltrated more frequently in RA patients in remission than patients in the active stage. Inactive RA patients with concomitant asthma developed a flare of disease after anti-IL-5 monoclonal antibody treatment, which might be explained reasonably by the depletion of rEos (8).

**ILC2–EOSINOPHIL–M2 MACROPHAGE AXIS COUNTERACTS JOINT INFLAMMATION**

As a messenger between the innate and adaptive immune systems, innate lymphoid cells (ILCs) have been realized to be intensely involved in the pathogenesis of inflammatory arthritis (52, 53). In particular, ILC2 acts as a crucial regulator in damping joint inflammation in contrast to proinflammatory ILC1/ILC3. Circulating ILC2 count was inversely correlated with disease activity index in RA patients and increased after receiving anti-rheumatic treatment (54). In line with these human data, genetic deletion of ILC2 in mice aggravated K/BxN serum-induced arthritis whereas expansion of ILC2 by IL-25/IL-33 mini-circles or adoptive transfer of ILC2 from wild-type but not IL-4–/– IL-13–/– mice attenuated arthritis (55). Furthermore, ILC2 was found to inhibit osteoclast differentiation and bone loss independently of inflammation (56).

Interestingly, it has been established that tissue-resident ILC2 regulates eosinophil homeostasis and accumulation into tissues through constitutive secretion of IL-5 (57). In asthmatic lung, ILC2 was the main producer of IL-5, which consequently drives the expansion and infiltration of rEos into the arthritic joints (8). Another recent work by us showed that activation of ILC2 by a small neuropeptide significantly suppressed the development of collagen-induced arthritis, accompanied by the expansion of eosinophils in the arthritic joints (10). In addition, induction of ILC2 by administration of IL-25/IL-33 accelerated the resolution of K/BxN serum-induced arthritis in wild-type but not eosinophil-deficient ΔdblGATA mice (8). On the contrary, neutralization of IL-5 by a monoclonal antibody blocked asthma-induced resolution of arthritis, with a reduced expansion of rEos in the joints (8). All these results supported the perspective that eosinophils are indispensable for ILC2-mediated resolution of arthritis (8).

Besides secreting a variety of pro-resolving lipid mediators that are crucial for the resolution of inflammation, the role of eosinophils in the suppression of arthritis could also include switching macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotype. As is well known, synovial macrophages act as central effector cells in the development of synovitis (3). The abundant presence of pro-inflammatory cytokines such as TNFα, IL-6, and IL-1β in the inflamed synovium suggests a predominant M1 macrophage phenotype in RA. However, the phenotype of synovial macrophages in vivo is highly complex and often exhibit a mixed polarization state (58). Previously it has been reported that even the same M1 macrophages recruited during the initial phase of arthritis can switch their phenotype toward M2 macrophages (59). In contrast to M1 macrophages that facilitate the inflammatory cascade in the synovium, M2 macrophages halt joint inflammation by removing dead cells (efferocytosis) and producing pro-resolving lipid mediators (58). It has been demonstrated that eosinophils induce polarization of macrophages toward M2 phenotype through secretion of IL-4, IL-13, and 12/15-LOX-derived lipid mediators (43). Eosinophil deficiency was associated with the impaired distribution of anti-inflammatory MHC-II macrophages in the steady state as well as in arthritis (7). Both in vitro and in vivo studies showed that eosinophils foster the polarization of M1 to M2 macrophages in the synovial tissue, partly via the IkB/P38 MAPK signaling pathway (8, 9). This is consistent with previous studies that reported that eosinophils in adipose tissue mediate macrophage differentiation into M2 phenotype, which are required for glucose homeostasis (60, 61). Taken together, the ILC2–eosinophil–M2 macrophage axis represents a novel and important immunological pathway counteracting joint inflammation and eliciting resolution of arthritis (Figure 1).

**FUTURE PERSPECTIVE IN THERAPY**

With accumulating evidence and advancing technologies, the classical view of eosinophils has changed from a pro-inflammatory cell in helminth infection and allergy to a cell type aggressively involved in anti-inflammatory responses in the resolution of chronic inflammation. The existence of rEos in the synovium of RA patients extended previous understanding that eosinophils are critical in counteracting joint inflammation and facilitating the resolution of disease. These findings are crucial for designing new approaches to rebalancing immune homeostasis in inflammatory arthritis, considering that current therapies are centered on inhibiting pro-inflammatory cytokines and mediators rather than fostering the resolution of inflammation. Hence, understanding how rEos are activated and expanded will offer a novel strategy for the development of safe and effective treatment for arthritis.

Indeed, it is well known that the major extrinsic driver of eosinophil expansion was helminth infection. Numerous previous studies in experimental mouse models have demonstrated clinical improvement of inflammatory activity in a variety of autoimmune and inflammatory diseases including RA (7, 62–67). These observations led to the proposal that harness helminth and their secreted products would represent a promising interventional approach for the treatment of RA, as supported by the findings that a filarial nematode-derived glycoprotein, ES-62, has been proved to exert an anti-inflammatory and anti-osteoclastogenic effect in mouse arthritis models (68–71). In addition, several clinical trials have been performed to evaluate the immune-regulatory effect of helminth on autoimmune diseases, especially in inflammatory bowel disease (72). The mechanisms by which
helminth and their derivatives modulate the host’s immune system were attributed to shifting immune responses from Th1 to Th2, induction of regulatory T and B cell subsets, as well as downregulation of IFN-γ and IL-17 (73). This helminth-based immunotherapy is becoming of major interest since current conventional management of RA relies generally on nonspecific inhibition of the immune system, which often results in severe infections and malignancies. Consistent with this concept, one of our recent studies showed that a small neuropeptide named Neumedin U successfully alleviated collagen-induced arthritis, with evidence of ILC2-eosinophil activation (10). On the other hand, the plasticity of eosinophils offers another strategy that induces differentiation of pro-inflammatory eosinophils into regulatory phenotypes.

CONCLUSION

In summary, emerging evidence has shown that eosinophils not only act as a pro-inflammatory effector cell but also display a pro-resolving feature in RA. They consistently reside in the synovium of RA patients in remission and proliferate under stimulation of ILC2-derived IL-5. Mechanistically, the rEos promote the resolution of arthritis through secreting resolvins in a 12/15-LOX-dependent manner and switching synovial macrophages into the M2 phenotype.

AUTHOR CONTRIBUTIONS

YQ, H-ZJ, and Y-JL drafted the manuscript. ZC revised the manuscript. All authors contributed to the discussion and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81871227 and 81501344).

REFERENCES

1. Bain BJ. Hypereosinophilia. Curr Opin Hematol (2000) 7(1):21–5. doi: 10.1097/00062752-200001000-00005
2. Klion AD, Ackerman SJ, Bochner BS. Contributions of Eosinophils to Human Health and Disease. Annu Rev Pathol (2020) 15:179–209. doi: 10.1146/annurev-pathmedchis-012419-032756
3. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid Arthritis. Nat Rev Dis Primers (2018) 4:18001. doi: 10.1038/nrdp.2018.1
4. Weyand CM, Goronzy JJ. The Immunology of Rheumatoid Arthritis. Nat Immunol (2021) 22(1):10–8. doi: 10.1038/s41590-020-00816-x
5. Kerschbaumer A, Seprano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Research Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis. Ann Rheum Dis (2020) 79(6):744–59. doi: 10.1136/annrheumdis-2019-216656
6. Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, et al. Challenges in the Treatment of Rheumatoid Arthritis. Autoimmun Rev (2019) 18(7):706–13. doi: 10.1016/j.autrev.2019.05.007
7. Chen Z, Andreev D, Oeser K, Krijlanac B, Hueber A, Kleyer A, et al. Th2 and Eosinophil Responses Suppress Inflammatory Arthritis. Nat Commun (2016) 7:11596. doi: 10.1038/ncomms11596
8. Andreev D, Liu M, Kachel K, Llerins Perez M, Kirchner P, Kolle J, et al. Regulatory Eosinophils Induce the Resolution of Experimental Arthritis and Appear in Remission State of Human Rheumatoid Arthritis. Ann Rheum Dis (2020) 80:451–68. doi: 10.1136/annrheumdis-2020-218902
9. Liu L, Zhang Y, Zheng X, Jin L, Xiang N, Zhang M, et al. Eosinophils Attenuate Arthritis by Inducing M2 Macrophage Polarization via Inhibiting the IkappaB/P38 MAPK Signaling Pathway. Biochem Biophys Res Commun (2019) 508(3):894–901. doi: 10.1016/j.bbrc.2018.12.010
10. Zhang Y, Qin Y, Chen Z. Neumedin U Suppresses Collagen-Induced Arthritis Through ILC2-Th2 Activation. J Immunol Res (2021) 2021:5599439. doi: 10.1155/2021/5599439
11. Rothenberg ME, Pomerantz JL, Owen WF Jr., Avraham S, Soberman RJ, Austen KF, et al. Characterization of a Human Eosinophil Proteoglycan, and Augmentation of Its Biosynthesis and Size by Interleukin 3, Interleukin 5, and Granulocyte/Macrophage Colony Stimulating Factor. J Biol Chem (1988) 263(27):13901–8. doi: 10.1016/S0021-9258(18)38329-2
12. Shalit M, Sekhsaria S, Mafech HL. Modulation of Growth and Differentiation of Eosinophils From Human Peripheral Blood CD34+ Cells by IL-5 and Other Growth Factors. Blood (1995) 85(11):3459–67. doi: 10.1182/blood.85.11.3459
13. Johnston LK, Hsu CL, Krier-Burnis RA, Chihua KD, Chien KB, McKenzie A, et al. IL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis. J Immunol (2016) 197(9):3445–53. doi: 10.4049/jimmunol.1600611
14. Hirasawa R, Shimizu R, Takahashi S, Osawa M, Takayanagi S, Kato Y, et al. Essential and Instructive Roles of GATA Factors in Eosinophil Development. Blood (2014) 123(10):1576–82. doi: 10.1182/blood-2013-06-009877
15. Acharya KR, Ackerman SJ. Eosinophil Granule Proteins: Form and Function. J Immunol (2012) 188(1):47–25. doi: 10.4049/jimmunol.1101980
16. MacKenzie JR, Mattes J, Dent LA, Foster PS. Eosinophils Promote Allergic Inflammation Recruited Professional Antigen-Presenting Cells. J Clin Immunol (2015) 35(1):3232–43. doi: 10.1007/s10875-014-00087-4
17. Acharya KR, Ackerman SJ. Eosinophil Granule Proteins: Form and Function. J Immunol (2012) 188(1):47–25. doi: 10.4049/jimmunol.1101980
18. Wang HB, Ghiran I, Matthaei K, Weller PF. Airway Eosinophils: Allergic Immunity and Draining Lymph Node Traf. FASEB J (2011) 25(2):561–8. doi: 10.1096/fj.10-170072
19. Weller SP, Spencer LA. Functions of Tissue-Resident Eosinophils. Nat Rev Immunol (2017) 17(12):746–60. doi: 10.1038/nri.2017.95
20. Acharya KR, Ackerman SJ. Eosinophil Granule Proteins: Form and Function. J Biol Chem (2014) 289(25):17406–15. doi: 10.1074/jbc.R113.546218
21. MacKenzie JR, Mattes J, Dent LA, Foster PS. Eosinophils Promote Allergic Disease of the Lung by Regulating CD4+(+) Th2 Lymphocyte Function. J Immunol (2001) 167(6):3146–55. doi: 10.4049/jimmunol.167.6.3146
22. Shalit M, Sekhsaria S, Mafech HL. Modulation of Growth and Differentiation of Eosinophils From Human Peripheral Blood CD34+ Cells by IL-5 and Other Growth Factors. Blood (1995) 85(11):3459–67. doi: 10.1182/blood.85.11.3459
23. Wagner LA, Christensen CJ, Dunn DM, Spangrude GJ, Georgelas A, Kelley L, et al. Eosinophil Deficiency Increases Eosinophil Progenitor Growth. J Immunol (2001) 167(6):3146–55. doi: 10.4049/jimmunol.167.6.3146
24. Wang HB, Ghiran I, Matthaei K, Weller PF. Airway Eosinophils: Allergic Inflammation Recruited Professional Antigen-Presenting Cells. J Immunol (2007) 179(11):7585–92. doi: 10.4049/jimmunol.179.11.7585
25. Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramzier R, Rosenberg HF, et al. Eosinophils Contribute to Innate Antiviral Immunity and Promote Clearance of Respiratory Syncytial Virus. Blood (2007) 110(5):1578–86. doi: 10.1182/blood-2007-01-071340
26. Soukup JM, Becker S. Role of Monocytes and Eosinophils in Human Respiratory Virus Infection. J Clin Immunol (2003) 107(3):178–85. doi: 10.1007/s10815-003-0038-X
27. Ueki S, Melo RC, Ghiran I, Spencer LA, Dvorak AM, Weller PF. Eosinophil Extracellular DNA Trap Cell Death Mediates Lytic Release of Free Secretion-Competent Eosinophil Granules in Humans. Blood (2013) 121(11):2074–83. doi: 10.1182/blood-2012-05-430208
28. Specht S, Saefeli M, Arndt M, Endl E, Dubben B, Lee NA, et al. Lack of Eosinophil Peroxidase or Major Basic Protein Impairs Defense Against Murine Filarial Infection. Infect Immun (2006) 74(9):5236–43. doi: 10.1128/IAI.01329-06
29. Wong CK, Cheung FP, Ip WK, Lam CW. Intracellular Signaling Mechanisms Regulating Toll-Like Receptor-Mediated Activation of Eosinophils. Am J Respir Cell Mol Biol (2007) 37(1):85–96. doi: 10.1165/rcmb.2006-0457OC
30. Padigel UM, Lee JJ, Nolan TJ, Schad GA, Abraham D. Eosinophils can Function as Antigen-Presenting Cells to Induce Primary and Secondary Immune Responses to Strongyloides Stercoralis. Infect Immun (2006) 74(6):3232–8. doi: 10.1128/IAI.02067-05
31. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF. Lymph Node Trafficking and Antigen Presentation by Endobronchial Eosinophils. J Clin Invest (2000) 105(7):945–53. doi: 10.1172/JCI8945
32. Radke AL, Reynolds LE, Melo RC, Dvorak AM, Weller PF, Spencer LA. Mature Human Eosinophils Express Functional Notch Ligands Mediating Eosinophil Autocrine Regulation. Blood (2009) 113(13):3992–101. doi: 10.1182/blood-2008-05-155937
33. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of Distinct CD4 T Helper Cell Fates by Different Notch Ligands on Antigen-Presenting Cells. Cell (2004) 117(4):515–26. doi: 10.1016/S0092-8674(04)00451-9
34. Schwab JM, Kiyokawa MA, Pearce EF. Schistosoma Mansoni Egg-Induced IL-4 Production Is Dependent Upon IL-5 and Eosinophils. J Exp Med (1996) 184(5):1871–8. doi: 10.1084/jem.184.5.1871
35. Voehringer D, Shinkai K, Locksley RM. Type 2 Immunity Reflects Orchestrated Recruitment of Cells Committed to IL-4 Production. Immunity (2004) 20(3):267–77. doi: 10.1016/S1074-7613(04)00026-3
36. Abe T, Sekhsaria S, Mafech HL. Modulation of Growth and Differentiation of Eosinophils From Human Peripheral Blood CD34+ Cells by IL-5 and Other Growth Factors. Blood (1995) 85(11):3459–67. doi: 10.1182/blood.85.11.3459
37. Gebeselasse NG, Meacham JF, Belvisi M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immunol (2016) 7:160. doi: 10.3389/fimmu.2016.00160
38. Serhan CN. Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology. Nature (2014) 510(7503):92–101. doi: 10.1038/nature13479
39. Serhan CN. Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology. Nature (2014) 510(7503):92–101. doi: 10.1038/nature13479
40. Serhan CN, Levy BD. Resolvins in Inflammation: Emergence of the Pro-Resolving Superfamily of Mediators. J Clin Invest (2012) 128(7):2657–69. doi: 10.1172/JCI97943
41. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvins El and Protectin D1 Activate Inflammation-Resolution Programmes. Nature (2007) 447(7146):869–74. doi: 10.1038/nature05877
42. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvins El and Protectin D1 Activate Inflammation-Resolution Programmes. Nature (2007) 447(7146):869–74. doi: 10.1038/nature05877
43. Serhan CN. Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology. Nature (2014) 510(7503):92–101. doi: 10.1038/nature13479
44. Serhan CN, Levy BD. Resolvins in Inflammation: Emergence of the Pro-Resolving Superfamily of Mediators. J Clin Invest (2012) 128(7):2657–69. doi: 10.1172/JCI97943
45. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvins El and Protectin D1 Activate Inflammation-Resolution Programmes. Nature (2007) 447(7146):869–74. doi: 10.1038/nature05877
Qin et al. Eosinophils in Resolution of Arthritis

54. Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, et al. Resolution of Inflammation by Interleukin-9-Producing Type 2 Innate Lymphoid Cells. Nat Med (2017) 23(8):938–44. doi: 10.1038/nm.4373

55. Omata Y, Frech M, Primbts T, Lucas S, Andreou D, Schötysek C, et al. Group 2 Innate Lymphoid Cells Attenuate Inflammatory Arthritis and Protect From Bone Destruction in Mice. Cell Rep (2018) 24(1):169–80. doi: 10.1016/j.celrep.2018.06.005

56. Omata Y, Frech M, Lucas S, Primbts T, Knipfer L, Wirtz S, et al. Type 2 Innate Lymphoid Cells Inhibit the Differentiation of Osteoclasts and Protect From Ovariectomy-Induced Bone Loss. Bone (2020) 136:115335. doi: 10.1016/j.bone.2020.115335

57. Nussbaum JC, Van Dyken SJ, von Mollike J, Cheng LE, Mohapatra A, et al. Resolution of Inflammation by Interleukin-9-Producing Type 2 Innate Lymphoid Cells Controls Eosinophil Homeostasis. Nature (2013) 502(7470):245–8. doi: 10.1038/nature12526

58. Kennedy A, Fearon U, Veale DJ, Godson C. Macrophages in Synovial Fibrosis: Nonclassical Ly6C(-) Monocytes Drive the Development of Inflammatory Arthritis in Mice. Cell Rep (2014) 9(2):591–604. doi: 10.1016/j.celrep.2014.09.032

59. Misharin AV, Cuda CM, Saber R, Turner JD, Gierut AK, Haines GK3rd, et al. Type 2 Innate Lymphoid Cells Control Eosinophil Inflammation by Interleukin-9-Producing Type 2 Innate Lymphoid Cells. Nature (2013) 502(7470):245–8. doi: 10.1038/nature12526

60. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Joulhan HA, Bando JK, et al. Eosinophils Sustain Adipose Alternatively Activated Macrophages Associated With Glucose Homeostasis. Science (2011) 332(6026):243–7. doi: 10.1126/science.1201475

61. Qin L, Odegaaard JJ, Cui X, Tian X, Locksley RM, et al. Eosinophils and Type 2 Cytokine Signaling in Macrophages orchestrate Development of Functional Beige Fat. Cell (2014) 157(6):1292–308. doi: 10.1016/j.cell.2014.03.066

62. Cheng Y, Zhu X, Wang X, Zhuang Q, Huyan X, Sun X, et al. Trichinella Spiralis Infection Mitigates Collagen-Induced Arthritis via Programmed Death 1-Mediated Immunomodulation. Front Immunol (2018) 9:1566. doi: 10.3389/fimmu.2018.01566

63. Sarter K, Kulagin M, Schett G, Harris NL, Zais MM. Inflammatory Arthritis and Systemic Bone Loss Are Attenuated by Gastrointestinal Helminth Parasites. Autoimmunity (2017) 50(3):151–7. doi: 10.1080/08916934.2016.1261837

64. Osada Y, Morita K, Tahara S, Ishihara T, Wu Z, Nagano I, et al. Thz Signals Are Not Essential for the Anti-Arthritic Effects of Trichinella Spiralis in Mice. Parasite Immunol (2020) 42(1):e12677. doi: 10.1111/pim.12677

65. Osada Y, Shimizu S, Kumagai T, Yamada S, Kanazawa T. Schistosoma Mansoni Infection Reduces Severity of Collagen-Induced Arthritis via Down-Regulation of Pro-Inflammatory Mediators. Int J Parasitol (2009) 39(4):457–64. doi: 10.1016/j.ijpara.2008.08.007

66. Shi M, Wang A, Prescott D, Waterhouse CC, Zhang S, McDougall JJ, et al. Infection With an Intestinal Helminth Parasite Freund's Complete Adjuvant-Induced Monoarthritis in Mice. Arthritis Rheum (2011) 63(2):134–44. doi: 10.1002/art.30098

67. Song X, Shen J, Wen H, Zhong Z, Luo Q, Chu D, et al. Impact of Schistosoma japonicum Infection on Collagen-Induced Arthritis in DBA/1 Mice: A Murine Model of Human Rheumatoid Arthritis. PloS One (2011) 6(8):e23453. doi: 10.1371/journal.pone.0023453

68. Doonan J, Lumb FE, Pineda MA, Tarafdar A, Crowe J, Khan AM, et al. Protection Against Arthritis by the Parasitic Worm Product ES-62, and Its Drug-Like Small Molecule Analogues, Is Associated With Inhibition of Osteoclastogenesis. Front Immunol (2018) 9:1016. doi: 10.3389/fimmu.2018.01016

69. Rzepecka J, Pineda MA, Al-Riyami L, Rodgers DT, Huggan JK, Lumb FE, et al. Prophylactic and Therapeutic Treatment With a Synthetic Analogue of a Parasitic Worm Product Prevents Experimental Arthritis and Inhibits IL-1beta Production via NRF2-Mediated Counter-Regulation of the Inflammome. J Autoimmun (2015) 60:59–73. doi: 10.1016/j.jaut.2015.04.005

70. Rodgers DT, Pineda MA, McGrath MA, Al-Riyami L, Harnett W, Harnett MM. Protection Against Collagen-Induced Arthritis in Mice Afforded by the Parasitic Worm Product, ES-62, Is Associated With Restoration of the Levels of Interleukin-10-Producing B Cells and Reduced Plasma Cell Infiltration of the Joints. Immunology (2014) 141(3):457–66. doi: 10.1111/imn.12208

71. Pineda MA, McGrath MA, Smith PC, Al-Riyami L, Rzepecka J, Gracie JA, et al. The Parasitic Helminth Product ES-62 Suppresses Pathogenesis in Collagen-Induced Arthritis by Targeting the Interleukin-17-Producing Cellular Network at Multiple Sites. Arthritis Rheum (2012) 64(10):3168–78. doi: 10.1002/art.34581

72. Fleming JO, Weinstock JV. Clinical Trials of Helminth Therapy in Autoimmune Diseases: Rationale and Findings. Parasite Immunol (2015) 37(6):277–92. doi: 10.1111/pim.12175

73. Bashi T, Bizzaro G, Ben-Ami Shor D, Blank M, Shoenfeld Y. The Mechanisms Behind Helminth’s Immunomodulation in Autoimmunity. Autoimmun Rev (2015) 14(2):98–104. doi: 10.1016/j.autrev.2014.10.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Qin, Jin, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.